Condition
Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Total Trials
5
Recruiting
3
Active
4
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
Early P 1 (1)
P 2 (1)
Trial Status
Recruiting3
Active Not Recruiting1
Not Yet Recruiting1
Clinical Trials (5)
Showing 5 of 5 trials
NCT07553338Phase 2Not Yet RecruitingPrimary
Safety Assessment of Leronlimab and Its Effect on Brain Inflammation in Alzheimer's Disease
NCT04075435Early Phase 1Active Not Recruiting
Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia
NCT06618807Not ApplicableRecruitingPrimary
Infrared Light for Memory Loss in Mild Cognitive Impairment (MCI)
NCT06792877Not ApplicableRecruiting
Mindfulness for Cognition in Early-stage Alzheimer's Disease
NCT06058234Recruiting
Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study
Showing all 5 trials